REMAP-ILD: Randomised, embedded, multifactorial, adaptive platform trial for interstitial lung disease
REMAP-ILD is an inclusive global collaborative project which will develop the first international platform trial in Interstitial Lung Disease (ILD), accelerating identification of effective and novel therapies in fibrotic ILD (FILD).
We welcome new collaborators to join our network. If you would like to get involved or find out more, please contact firstname.lastname@example.org. If you are a patient or representative from a patient organisation and would like to get involved, please contact email@example.com. You might also find this additional information helpful too.
Interstitial Lung Diseases (ILDs) represent a group of fibro-inflammatory disorders that occur following exposure to a variety of dusts, in association with diseases (e.g. rheumatoid arthritis, sarcoid), or, in cases of Idiopathic Pulmonary Fibrosis (IPF), without known cause. In many cases the fibrosis becomes autonomous and progressive with worse outcomes than many cancers. Anti-fibrotic therapy (nintedanib and pirfenidone) is available, however, they are expensive and have numerous side effects. Furthermore, these drugs do not represent a cure and offer no improvement in long-term survival or quality of life. Unfortunately, at the current time, drug development can take many years for a single asset, and therefore there is an urgent need to accelerate drug develop for patients with fibrotic interstitial lung disease (FILD).
The goal of REMAP-ILD is to design a clinical trial which can speed up the assessment of therapies for patients with FILD. We will achieve this by creating an international platform to carry out clinical trials that rapidly assess potential treatments. We will use a new approach to trial design that will enable multiple therapies to be assessed at the same time, which are known as Randomized, Embedded, Multifactorial, Adaptive Platform (REMAP) trials and we will shorten the time it takes to decide if a therapy is working or not. We want to make it easy for patients to take part in the trial by minimising the number of hospital visits and disruption to their lives.
The results of the clinical trial will allow many more treatments including currently available medicines, new therapies and non-drug treatments to be assessed in a much shorter period of time. Ultimately, this will mean patients diagnosed with this devasting disease will have access to therapies that will enable them to live well for longer.
In partnership with Action for Pulmonary Fibrosis, our first REMAP-ILD patient and public involvement and engagement event is being held on the 1st of November 2022, 7pm-8.30pm.
For registration and to learn more about this inspiring event, please follow the link: https://www.actionpf.org/news/www-actionpf-org-news-remap-ild
Adaptive and Platform Trials: Can we REMAP-ILD?
Dr Roger Lewis, Senior Medical Scientist for Berry Consultants, presents a talk on 'Adaptive and Platform Trials: Can we REMAP-ILD?'
An introduction and overview to REMAP-ILD:
An introduction and overview of REMAP-ILD was presented through a series of talks at the 21st International Colloquium on Lung and Airway Fibrosis (ICLAF) 2022. Professor Gisli Jenkins, Dr Leticia Kawano-Dourado, Professor Roger Lewis, Professor Naftali Kaminski and Dr Wendy Adams close the sessions with a panel discussion and Q&A.
REMAP-ILD educational event
The REMAP-ILD virtual education event discussed why this research is needed and how this new type of clinical trial design could help find treatments faster. Attendees also heard from patients and family members on why they think this project is important and why they are getting involved